Species |
Human |
Protein Construction |
CEACAM-3/CD66d (Lys35-Gly155) Accession # P40198-1 |
hFc |
N-term |
C-term |
|
Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
Endotoxin Level |
Less than 1EU per μg by the LAL method. |
Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized Human CEACAM7, His Tag at 1μg/ml (100μl/well) on the plate can bind CEACAM-3/CD66d hFc Chimera, Human. Test result was comparable to standard batch. |
Expression System |
HEK293 |
Theoretical Molecular Weight |
39.85 kDa |
Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 50-60 kDa based on Bis-Tris PAGE result. |
Formulation |
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). |
Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
Target Background |
The human granulocyte-specific receptor carcinoembryonic antigen-related cell adhesion molecule (CEACAM)3 is critically involved in the opsonin-independent recognition of several bacterial pathogens. CEACAM3-mediated phagocytosis depends on the integrity of an ITAM-like sequence within the cytoplasmic domain of CEACAM3 and is characterized by rapid stimulation of the GTPase Rac. |
Synonyms |
CEACAM3; CD66d; CGM1; CEA; |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.